Form 4: SOPHiA GENETICS CSO Executes Planned Share Sale

Chief Scientific Officer Zhenyu Xu sold 600 ordinary shares of SOPHiA GENETICS SA under a pre-arranged 10b5-1 trading plan.

Summary

• Zhenyu Xu, Chief Scientific Officer of SOPHiA GENETICS SA, sold 600 ordinary shares on April 14, 2026.
• The shares were sold at a weighted average price of $4.9663 per share.
• The transaction was executed pursuant to a Rule 10b5-1(c) trading plan, which allows insiders to set up a predetermined schedule for selling stocks.
• Following this transaction, the reporting person retains beneficial ownership of 631,496 ordinary shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale was a small, pre-planned transaction that does not materially alter the insider's significant remaining stake.

Positives

• The sale was conducted under a pre-established Rule 10b5-1 trading plan, indicating the transaction was not based on non-public information.

Negatives

• Insider selling can sometimes be perceived by the market as a lack of confidence in the short-term stock performance, though this was a small volume sale.

Risks

• Market volatility affecting the share price, which ranged from $4.82 to $5.16 during the execution of this specific trade.

Future Outlook

No specific forward-looking guidance regarding company operations was provided in this filing.

Management Comments

• The reporting person has committed to providing full information regarding the number of shares sold at each separate price within the $4.82 to $5.16 range upon request.

Industry Context

StockSavvy.ai notes that routine insider selling under 10b5-1 plans is a standard corporate practice for liquidity and diversification, and typically does not signal a change in fundamental company strategy or outlook.

Comparison to Industry Standards

• The use of Rule 10b5-1 trading plans is the industry standard for executives to manage equity holdings while avoiding potential insider trading allegations.

Stakeholder Impact

• Minimal impact on shareholders given the small volume of shares sold relative to the total holdings.

Next Steps

• No further actions or milestones were mentioned in this filing.

Key Dates

Keywords

SOPHiA GENETICS, SOPH, Insider Trading, Form 4, Zhenyu Xu, Biotech